MDGL Madrigal Pharmaceuticals, Inc.

NASDAQ
$540.06

Madrigal Pharmaceuticals, Inc. (MDGL) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with MDGL's own trailing one-year pace, with 75% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 2 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
9
202 transactions
Purchases
$0
0 shares
Sales
$81.5M
154,983 shares
Net activity
-$81.5M
purchases less sales

How much of that selling was preplanned? 75% planned / 25% discretionary

10b5-1 plan sales $61.5M 152 transactions · 114,917 shares
Discretionary sales $20.0M 50 transactions · 40,066 shares

Largest single sale: $4.0M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Sibold William John 10 fills President and CEO Sell 10b5-1 5,221 $542.39 $2.8M 202,907 −2.5% of holding
Sibold William John 14 fills President and CEO Sell 6,362 $535.59 $3.4M 209,198 −3% of holding
Kelley Shannon T General Counsel Sell 664 $514.97 $341.9K 11,474 −5.5% of holding
Sibold William John 10 fills President and CEO Sell 2,500 $547.30 $1.4M 211,689 −1.2% of holding
Soergel David Chief Medical Officer Sell 10b5-1 1,042 $495.74 $516.6K 10,033 −9.4% of holding
Levy Richard S 12 fills Director Sell 10b5-1 5,682 $515.44 $2.9M 27,657 −17% of holding
Soergel David Chief Medical Officer Sell 844 $515.90 $435.4K 11,075 −7.1% of holding
Sibold William John President and CEO Sell 1,663 $431.94 $718.3K 161,829 −1% of holding
Dier Mardi 11 fills EVP and CFO Sell 10b5-1 1,336 $430.36 $575.0K 13,786 −8.8% of holding
Dier Mardi EVP and CFO Sell 646 $431.94 $279.0K 13,826 −4.5% of holding
Taub Rebecca Director Sell 491 $431.94 $212.1K 452,213 −0.1% of holding
Huntsman Carole Chief Commercial Officer Sell 419 $431.94 $181.0K 12,692 −3.2% of holding
Kelley Shannon T General Counsel Sell 360 $431.94 $155.5K 12,138 −2.9% of holding
Dier Mardi EVP and CFO Sell 1,183 $427.21 $505.4K 9,257 −11.3% of holding
Sibold William John President and CEO Sell 1,577 $492.42 $776.5K 148,497 −1.1% of holding
Taub Rebecca Director Sell 647 $492.42 $318.6K 452,704 −0.1% of holding
Huntsman Carole Chief Commercial Officer Sell 10b5-1 570 $494.59 $281.9K 9,122 −5.9% of holding
Huntsman Carole Chief Commercial Officer Sell 340 $492.42 $167.4K 9,692 −3.4% of holding
Taub Rebecca Director Sell 2,238 $490.77 $1.1M 453,351 −0.5% of holding
Kelley Shannon T General Counsel Sell 10b5-1 429 $501.40 $215.1K 8,481 −4.8% of holding
Kelley Shannon T General Counsel Sell 263 $490.77 $129.1K 8,910 −2.9% of holding
FRIEDMAN PAUL A 29 fills Director Sell 10b5-1 24,800 $522.71 $13.0M 210,204 −10.6% of holding
Taub Rebecca 30 fills Director Sell 10b5-1 18,650 $522.76 $9.7M 473,039 −3.8% of holding
FRIEDMAN PAUL A 9 fills Director Sell 10b5-1 24,800 $552.18 $13.7M 211,340 −10.5% of holding
Taub Rebecca 9 fills Director Sell 10b5-1 18,650 $552.15 $10.3M 479,203 −3.7% of holding
Sibold William John President and CEO Sell 2,400 $575.34 $1.4M 150,074 −1.6% of holding
Dier Mardi 15 fills EVP and CFO Sell 10b5-1 4,173 $578.34 $2.4M 14,293 −22.6% of holding
Huntsman Carole 10 fills Chief Commercial Officer Sell 10b5-1 1,064 $554.91 $590.4K 10,952 −8.9% of holding
Huntsman Carole Chief Commercial Officer Sell 894 $550.97 $492.6K 11,096 −7.5% of holding
Levy Richard S 14 fills Director Sell 10b5-1 8,500 $520.96 $4.4M 29,551 −22.3% of holding
BATE KENNETH 11 fills Director Sell 16,575 $484.30 $8.0M 17,439 −48.7% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.